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Renal microvascular injury induced by antibody to glomerular
endothelial cells is mediated by C5b-9
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Renal microvascular injury induced by antibody to glomerular endo-
thelial cells is mediated by ('5h-9. We have recently developed a model of
thrombotic microangiopaths injury to the glomerular endothelial cell
(GEN) induced by heterologous antibody to rat GEN. In addition to GEN
injury rats developed glomerular platelet aggregation and fibrin deposi-
tion, acute renal failure, and acute tubular necrosis with interstitial
inflammation. To study the role of complement in mediating this lesion,
we induced the disease in normal complement PVC rats and measured the
effects of generali7ed complement depletion with cobra venom factor
(CVF) and of selective CO deficiency using genetically CO deficient PVG
animals. Complement sufficient rats developed severe endothelial injury
accompanied by platelet aggregation, fibrin deposition, decrease in endo-
thelial cells assessed by antibody staining in the glomerulus, and macro-
phage infiltration. These changes were associated with marked reduction
in renal function. These features were either absent or markedly dimin-
ished in complement depleted or C6 deficient rats. This dmonstrates that
C5b-9, the terminal product of activation of the complement cascade,
plays an important role in the pathogenesis of this immune renal
microvascular endothelial injury model. Thus, the complement system
may play a pathogenic role in renal microvascular diseases such as
thrombotic microangiopathy.
Increasing evidence implicates autoimmune mechanisms in the
pathogenesis of human glornerulonephritis [11. Models of glomer-
ular disease analogous to idiopathic membranous nephropathy
and mesangioproliferative glomerulonephritis can be induced in
rodents by administration of antibody to antigens expressed on
the membranes of the glomerular epithelial cells (GEC) and
mesangial cells, respectively [1—4]. Injury mediated by these
antibodies is largely complement dependent [4—61. In both eases,
the mechanism of the complement effect involves formation and
cell membrane insertion of the C5h-9 membrane attack complex
of complement [7—13]. In the ease of anti-GEC antibody (mem-
branous nephropathy) the effect of C5b-9 is non-lytic and involves
activation of the GEC to produce oxidants and proteases [I,
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14—191. With anti-mesangial cell antibody (ATS model) the C5b-9
effect probably involves cell lysis as well [7].
Although antibodies to endothelial cells are common in dis-
eases like vaseulitis [20—24], lupus nephritis [25—30], and hemo-
lytic uremic syndrome [31—34], the role of these antibodies in
mediating the disease process is not well defined. However, in
hyperacute allograft rejection and xenotransplantation, anti-en-
dothelial cell antibodies are the principal mediators of disease
[35—37]. Although the glomerular endothelial cell (GEN) is a
likely target in a variety of other renal diseases, there are no good
models of immune mediated injury to the GEN. We have recently
developed a new model of thrombotie microangiopathy with
features of hemolytic uremie syndrome induced by passive admin-
istration of heterologous antibody to rat GEN [38]. Features of
this model include renal microvascular injury with platelet aggre-
gation, fibrin deposition, and glomerular endothelial injury with
proliferation, interstitial disease and tubular necrosis.
To investigate the role of complement in mediating antibody-
induced injury to the GEN and its consequences, we examined the
effects of generalized complement depletion and tested the role of
C5b-9 by comparing disease in C6 deficient and normal PVG rats.
Our results indicate that endothelial injury in this model is
mediated primarily by the C5b-9 membrane attack complex of
complement.
METHODS
Induction of the renal TMA model
The renal TMA model was induced by selective perfusion of the
right kidney through the superior mesenteric artery with the
purified IgG fraction of anti-GEN antibody. The technique of
selective renal artery perfusion has been described previously [39].
Kidneys were perfused with 0.2 ml of saline, followed by 80 mg/kg
body wt of anti-GEN IgG or control non-immunized goat IgG in
phosphate-buffered saline (PBS), pH7.2. Ischemia time was less
than six minutes. The unperfused left kidney was removed prior to
closing the abdominal incision.
Immunization of goat with cultured rat glomerular endothelial
cells
Culture of rat GEN and the characterization of GEN have been
described elsewhere [401.
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A goat was immunized with 1 >< iO rat GEN in complete
Freund's adjuvant (Sigma Chemical Co., St. Louis, MO, USA)
and 0.9% saline subcutaneously at multiple sites. The goat was
boosted every month with 1 x io cells emulsified with incomplete
Freund's adjuvant and 0.9% saline. After the second boost the
goat was plasmapheresed 10 days following immunization and
IgG was purified from the goat plasma as described below.
Purification of goat IgG
Goat IgG for renal artery perfusion was purified utilizing a
caprylic acid precipitation method as described before [41, 42].
Briefly, after adjusting the pH of the plasma to 5.5 with HC1, 5.5
ml/100 ml plasma of caprylic acid solution (Sigma) was added in
a dropwise fashion with vigorous stirring. The solution was then
stirred for one hour at room temperature and centrifuged at 14K
rpm for 30 minutes at room temperature. The supernatant was
collected and dialyzed against PBS. The dialyzed solution was
centrifuged at 14K rpm for 30 minutes at 4°C. This supernatant
was sterilized by filtration and stored at 4°C.
Experimental animals
To investigate the roles of the complement system in the
pathogenesis of this model, we employed PVG rats. Male PVG
rats weighing 200 to 300 grams were obtained from two separate
vendors. PVG rats with normal complement activity were ob-
tained from Harlan Sprague-Dawley (Indianapolis, IN, USA).
Age and sex matched C6-deficient PVG rats were obtained from
Bantin and Kingman Universal (Edmonds, WA, USA). All animal
studies were performed in an accredited animal care facility in
accord with the National Institutes of Health (NIH) guidelines for
the Care and Use of Laboratory Animals. All rats were assessed
for complement activity by CH5O assay before the study. Comple-
ment component analysis in PVG rats has been reported previ-
ously [7, 43].
Experimental protocol
To investigate the role of the complement system in the
pathogenesis of this model, we employed PVG rats. Four groups
of rats were studied. Group I was composed of complement
sufficient PVG rats (N = 5). Group II was composed of comple-
ment sufficient PVG rats depleted of complement with CVF
treatment (N = 6). Group III was composed of C6-deficient PVG
rats (N = 6). These three groups were perfused with anti-GEN
IgG. Group IV was composed of complement sufficient PVG rats,
and were perfused with normal goat IgG and served as a negative
control (N = 3). To deplete complement in rats in group II, 125
sg of CVF (Calbiochem, La Jolla, CA, USA) was administered
intraperitoneally one day before induction of the disease. Rats in
groups I and III received vehicle only instead of CVF. Comple-
ment depletion in group II rats and complement deficiency in
group III rats were confirmed by measurements of CH5O. Blood
samples were collected from the tail vein at day —1, just before
induction of the disease, and at day ito examine the complement
status. Four hours after surgery, a survival renal biopsy was
performed. Rats were then housed in metabolic cages with free
access to water, and the urine was collected overnight. Twenty-
four hours after induction of disease, a blood sample was obtained
via cardiac puncture, and the kidney was biopsied for histologic
studies.
Renal histology
Methyl Carnoy's fixed tissue was processed, and 4 m sections
were stained with the following antibodies. Glomerular platelet
infiltration was assessed by staining with PL-1, a murine mono-
clonal antibody to rat platelets (generously supplied by W.W.
Baker, University of Groningen, Groningen, the Netherlands)
[44]. Glomerular endothelial cells were stained with RECA-1, a
monoclonal IgG1 antibody specific for endothelial cells [5I.
Glomerular macrophages were stained with the monoclonal
antibody ED-I (Bioproducts for Science, Indianapolis, IN, USA)
at a final concentration of 0.4 tg/ml. The macrophages present
per glomerular cross-section were counted in a blinded fashion.
Twenty randomly selected glomeruli were examined per rat, and
the average number of positive cells per glomerulus was calcu-
lated. Glomerular cross-sections containing only a minor portion
of the glomerular tuft (< 20 discrete capillary segments per
cross-section) were not utilized. The cortical interstitial macro-
phage number was measured as described previously [46]. Briefly,
the number of ED-i positive cells was expressed as the mean SD
number per high power field (hpf). This value was calculated
from counts made on 25 randomly selected cortical interstitial
areas per individual rat kidney in mid-coronal sections in a
blinded fashion.
Tissue for immunofluorescence was embedded in O.C.T. (Lab-
Tek Products, Miles Laboratories, Naperville, IL, USA) and
snap-frozen in isopentane. Fibrinogen was detected by staining
with FITC-conjugated goat anti-fibrinogen IgG (Cappel Labora-
tories, Durham, NC, USA) at a final concentration of 25 ig/ml.
Rat C3 was detected with FITC-conjugated goat anti-rat C3
(Cappel). The presence of rat CSb-9 was determined using a
biotinylated anti-rat C5b-9 monoclonal antibody 2A1 [47], fol-
lowed by FITC-streptavidin.
Electron microscopy
Tissue for electron microscopy (EM) was fixed in half-strength
Karnovsky's solution (1% paraformaldehyde and 1.25% glutaral-
dehyde in 0.1 M Na cacodylate buffer, pH 7.0), postfixed in
osmium tetroxide, dehydrated in graded ethanols, and embedded
in epoxy resin. Thin sections were stained with uranyl acetate and
lead citrate and examined with a Philips 410 (Philips Export BV,
Eindhoven, The Netherlands) electron microscope.
Serum CH5O, blood urea nitrogen, and urinary protein
measurement
To examine the effect of CVF, the hemolytic activity of
complement was measured by the hemolysis of sheep eiythrocytes
sensitized by specific antibodies (anti-sheep hemolysin) and com-
pared to serum taken from the rats prior to treatment [48]. The
degree of hemolysis is expressed in CH5O units. One CH5O unit is
defined as the volume of serum that will lyse fifty percent of the
erythrocytes in the reaction mixture. The number of CH5O units in
I ml of serum is the hemolytic titer.
Blood urea nitrogen (BUN) was determined colorimetrically
utilizing a commercial kit for the measurement of urea nitrogen
(Sigma Diagnostics).
Urine protein excretion was measured using the sulfosalicylic
acid method [49].
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Fig. 1. Anti-glomerular endothelial cell (GEN) tgG deposition was not different among three different groups of rats. Anti-goat IgG antibody detected
deposition of anti-GEN IgG in the glomerular capillary walls with the same intensity in all three groups (A, group I; B, group II; C, group III)
(magnification X400).
Fig. 2. C3 deposition in the glomerulus of anti-
glomerular endothelial cell (GEN) IgG
perfused rats CA). In complement sufficient rats
(group I), C3 deposition was observed in the
glomerular capillary walls four hours after the
perfusion. (B) In complement depleted rats
(group II), no C3 deposition was observed. (C)
In C6 deficient rats (group Ill), C3 staining was
observed along the glomerular endothelium.
The increased staining in group III than group
I may reflect better preservation of the
endothelium in this group (magnification
x400).
Statistical analysis
Data were reported as mean SD. Data were analyzed by
Student's I-test with adjustments using the Bonferroni/Dunn
method.
RESULTS
Glomerular deposition of anti-glomerular endothelial cell IgG
was similar among group I, II, and HI rats
To examine if there was a difference in binding of anti-GEN
lgG to the glomerulus among rats in different groups, the biopsies
obtained four hours after induction of disease were stained with
anti-goat IgG. All the rats in groups 1, II, and III demonstrated
intense endothelial staining with anti-goat IgG without any de-
tectable differences between groups (Fig. 1). Rats of group TV
showed minimal staining.
Acute renal failure with decrease of C1150 was observed only in
complement sufficient group I rats
The BUN was measured one day after induction of disease.
Both CVF treated rats (group TI) and C6 deficient rats (group III)
showed BUN levels comparable to negative control rats (group
IV) (28.3 4.2 mg/dl, 29.9 4.3, 28.3 4.1, respectively, P >
0.05). However, complement sufficient rats (group 1) demon-
strated severe renal failure with BUN levels of 186.1 17.8 mg/dl
(P < 0.0001). Urinary protein excretion was less in group I rats
(7.2 5.0 mg/day) compared with group II rats (21.7 3.3),
group III rats (25.8 3.5), and negative control rats (23.8 3.4).
Acute renal failure in group I rats was accompanied by a decrease
in CH5O to 69.5 7.6% of its previous value prior to induction of
disease, while that of negative control rats was 95.1 17.8% (P =
0.09).
C3 and C5b-9 staining
To examine if deposition of complement components occurred
in this model, we performed immunofluorescence studies. Biop-
sies at four hours were used for C3 staining, while those at day I
were utilized for CSb-9 staining. The glomerulus of group I rats
were positive for both C3 and C5b-9 staining (Figs. 2A and 3A).
The glomerulus of group TI and group IV animals were negative
for both C3 and C5h-9 (Figs. 2B and 3B). The glomerulus of
group III rats were C3 positive and C5b-9 negative (Figs. 2C and
3C), which was consistent with its C6 deficient status. The staining
of C3 in group III rats showed a clear endothelial pattern in the
glomerulus, while that in group I rats was more hazy, reflecting
the damaged endothelium in these animals. We also observed
tubular staining for C5b-9 in group I rats (Fig. 3A), which is often
seen in many proteinuric diseases and believed to be consequent
to intraluminal C5b-9 formation in proteinurie urine. Negative
control rats (group IV) showed no staining for either C3 or C5b-9.
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Fig. 3. C5b-9 deposition in the glomerulus of
anti-glomerular endothelial cell (GEN) tgG
perfused rats (A) CSb-9 was detected along the
glomerular capillary walls in complement
sufficient rats (group I). (B) C5b-9 was not
observed in the complement depleted rats
(group II). (C) C5b-9 was not detectable in the
C6 deficient rats (group III) (magnification
x400).
Fig. 4. Fibrinogen deposition was observed
only in complement sufficient rats.
Complement sufficient rats (group I) showed
fibrinogen deposition in the glomerular
capillary loops CA), while no deposition was
observed in either complement depleted rats
(group II, B) or C6 deficient rats (group III, C)
(magnification ><400).
Fig. 5. Platelet aggregation was observed only in complement sufficient rats. Marked platelet aggregation was seen only in complement sufficient rats
(group IA), while neither complement depleted rats (group IT, B) nor C6 deficient rats (group III, C) showed platelet aggregation. Note that platelet
aggregation was not only in the glomerular capillary loops, but also in the peritubular capillaries in group I rats (magnification ><400).
Glomerular deposition of platelets and fibrin was observed only
in complement sufficient group I rats
We examined platelet aggregation and fibrin deposition in
glomeruli. Marked aggregation of platelets was observed only in
group I rats, while rats of group II and III showed no platelet
aggregation (Fig. 5). Fibrin deposition was also observed only in
group I rats (Fig. 4). Neither platelet aggregation nor fibrin
deposition occurred in negative control rats (group IV).
Macrophage infiltration was observed only in the interstitium
of complement sufficient group I rats
Macrophage infiltration was assessed 24 hours after induction
of disease. The number of macrophages in glomeruli of group
rats did not differ from those of group II, III, and IV rats (0.36
0.13 macrophages per glomerular cross-section, 0.62 0.40,
0.30 0.13, and 0.43 0.15, respectively; P > 0.05). However,
macrophage infiltration in the interstitium of group I rats was
significantly greater than those of group II, III, and IV rats
(7.26 1.51 macrophages per high power field, 3.22 1.16,
2.70 1.17, and 1.27 0.91, respectively; P < 0.0001). Although
the numbers of interstitial macrophages of group II and III rats
were higher than that of group IV rats, the differences were not
statistically significant.
Glomerular endothelial cell damage was observed only in
complement sufficient group I rats
Glomerular endothelial cell (GEN) morphology was assessed
24 hours after induction of disease by staining with the endothelial
cell specific monoclonal antibody, RECA-1. Most glomeruli of
group I rats showed some decrease in RECA-1 staining, indicating
damage to GEN, while glomeruli of group II and III rats showed
intact RECA-1 staining patterns that were not different from that
in group IV rats (Fig. 6).
These histological, immunohistochemical, and immunofluores-
cence studies are summarized in Table 1.
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Fig. 6. Damage of glomerular endothelial cells
(GEN) was observed only in complement
sufficient rats. A decrease of RECA-1 staining
was observed in the glomeruli of group I rats
(A), indicating destruction of GEN, while
glomeruli of group 11(B) and III (C) rats
showed intact RECA-1 staining patterns
(magnification X400).
Table 1. Histological and immunochemical analyses
Goat
lgG C3 C5b-9 PAS Fibrin PL-1 Mø RECA-1
Group I ++ ++ ++ ++ ++ ++ ++(7.26) +
Group II ++ — — — — — + (3.22) ++
Group III ++ ++ — — — — + (2.70) ++
Group IV — —
—
— — — + (1.27) ++
Abbreviations are: PAS, histological damages judged by PAS staining;
MØ, macrophage infiltration in the interstitium. Numbers are represented
as macrophages per high power field.
Electron microscopic analysis
To confirm our histological and immunohistochemical data, we
performed electron microscopic analysis. In complement suffi-
cient group I rats, glomeruli demonstrated widespread aggrega-
tion of platelets within capillary lumina. Many platelets could be
seen adherent to the capillary endothelium. In some loops fibrin
thrombi were present. Glomerular endothelium was frequently
swollen and endothelial denudation from basement membranes
was observed (Fig. 7A), although in some capillary loops the
accumulation of platelets and fibrin developed in the absence of
niorphologically detectable changes to the fenestrated endothelial
lining (Fig. 7B).
In contrast, no abnormal electron microscopic findings were
demonstrated in CVF treated group II rats (Fig. 7C). C6-deficient
group III rats showed occasional intraluminal platelet aggregates
similar to those encountered in C6 sufficient rats of group I, but
the frequency of this finding was considerably less than that
encountered in group I animals. Most glomerular capillaries of
group III animals were without identifiable abnormalities and
indistinguishable from the capillaries of group II animals.
DISCUSSION
Here we describe the role of complement in a new renal
microvascular injury model in rats utilizing both complement
depletion with CVF and a genetically C6-deficient rat strain. C6
deficiency in the PVG rat was first reported by Leenaerts et al
[43], and since then this strain has been utilized to study various
complement-mediated processes including glomerulonephritis [7,
50—52]. Our studies described here demonstrate that renal injury
in this model is complement-dependent through mechanisms that
apparently involve C5b-9 formation.
The BUNs of the complement sufficient rats at day I were very
high, while BUNs of complement depleted and C6 deficient rats
were not different from that of negative control rats. Some of this
increase in BUN may reflect intravascular hemolysis that occurs in
this model. The absence of proteinuria in the complement suffi-
cient rats probably reflects severe acute renal failure.
In this study complement depleted and C6 deficient rats not
only maintained normal renal function despite apparently similar
amounts of antibody deposition, but also showed either absent
(complement depleted) or markedly diminished (C6 deficient)
histological features of injury. Nephritogenic consequences of
complement activation include generation of chemotactic factors
such as C5a and formation of the C5b-9 membrane attack
complex [15, 16]. Although chemotactic factors are generally
regarded as the principal mediator of complement dependent
lesions involving circulating inflammatory cells, C5b-9 can also
stimulate production of cytokines such as inflammatory mediators
and extracellular matrix components by resident glomerular cells
[53—59]. In rats complement depleted with CVF, there is neither
generation of local inflammatory mediators derived from the
cleavage of complement components nor the C5b-9 terminal
membrane attack complex, which was supported by negative
staining of C3 and CSb-9. In contrast, C6 deficient rats can
generate functional protein products proximal to C6 in the
complement cascade, while they cannot make C5b-9, which was
supported by positive staining of C3 and negative staining of
C5b-9. Since the beneficial effects of generalized complement
depletion were largely replicated in C6 deficient rats, which could
generate C5a, our results suggest that C5b-9 is responsible for
most of the complement-mediated injury observed.
These results contrast with previous studies of the concanavalin
A (con A)!anti-con A model of subendothelial immune complex
glomerulonephritis induced by local binding of antibody to an
antigen planted on the inner surface of the capillary wall [60—62].
The con A model is also complement-dependent but primarily
through complement interactions with neutrophils, suggesting a
primary role for complement-derived chemotactic factors rather
than C5b-9 [62—64]. This is supported by preliminary studies of
the con A model in PVG rats that demonstrated no major
differences in C6 deficient animals (data not shown). The reasons
for this discrepancy are unclear, but may reflect the much greater
quantity of fixed antigens available in con A model compared to
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Fig. 7. Electron nuicroseopc analysis. (A)
Platelet ricn ;reebi dlOmerular capillaries
such as these were \s'idesp iead ii complement
sufficient ani:es 1:&'Ot y3) Iiitracapillaiy
thrombi in co:•i; replete rats. In some
capillary loops, -e.e:u :euat13ns of platelets and
evidence of thr .:oos were present at times
when the fenestrated endothelial lining of
glonierular capillaries remained preserved
(arrows) (x &O). (C) Glomerutar capillaries
were lree of ihrnmbosis in animals treated with
cobra venom ta:,i (x4600).
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antigens on the membrane of GEN, which are less important and
may be quickly shed [65, 66].
The mechanism of the C5b-9 nephritogenic effect in this model
is not established by this study. One possibility is that C5b-9 simply
lyses endothelial cells, leading to denudation of basement mem-
brane with subsequent platelet aggregation and thrombosis. While
some lysis may occur in this model, the ultrastractural studies
show an intact glomerular endothelium in most capillaries. A
more likely possibility, therefore, is that C5b-9 in sublytic quanti-
ties impacts directly on vascular homeostatic mechanisms, evoking
cellular responses that serve to both promote adherence of blood
cells to the vessel walls and the formation of fibrin through the
enzymatic cascades of the coagulation system [67—701. The mech-
anisms of fibrin deposition and platelet activation mediated by
C5b-9 are multifactorial. C5b-9 attack results in secretion of
multimers of von Willebrand factor from endothelial cells [71]
and stimulated expression of endothelial prothrombinase activity
[72], which contribute to fibrin deposition and platelet activation.
Recently it was shown that assembly of C5b-9 induces expression
of tissue factor on endothelial cell surfaces, which induces proco-
agulant activity in endothelium [731. Furthermore, C5b67 induces
alterations in cell shape and the cytoskeleton of endothelium that
disrupt monolayer integrity and lead to formation of intercellular
"gaps," which may expose preexisting inducers of thrombosis in
the underlying matrix, to plasma clotting factors and platelets [74].
Complement-mediated injury also releases heparan sulfate pro-
teoglycan from endothelial cells [75], which may decrease the
availability of antithrombin III and impair control of thrombin. In
this model of renal microvascular endothelial injury, widespread
platelet aggregation and fibrin deposition was observed only in
group I rats, which suggests that endothelial injury induced by
C5b-9 plays an important role in these events. Endothelial injury
was most prominent in group I rats, which was confirmed by
RECA-1 staining.
Our model is induced by renal artery perfusion of anti-GEN
antibody. Anti-endothelial cell antibodies (AECA) have been
described in many conditions including glomerulonephritis [76—
80]. In SLE, which is known to show renal TMA, there is an
association between the presence of AECA and nephritis [25, 26,
28—30]. Although one report demonstrated fixation of comple-
ment in vitro by anti-endothelial cell antibodies from patients with
SLE [27], most authors have been unable to confirm complement-
mediated cytotoxicity of the anti-endothelial cell antibodies from
various connective tissue disease patients on endothelial cells [21,
22, 24, 81]. However, sublytic effects of C5b-9 resulting in
activation of GEN to produce inflammatory mediators has not
been excluded. Primary antiphospholipid syndrome is also known
to be associated with renal microvascular endothelial injury
[82—85], and patients with primary antiphospholipid syndrome
have been shown to possess AECA [86—88]. Anti-endothelial cell
antibodies (AECA) were also demonstrated in serum from pa-
tients with hemolytic uremic syndrome (HUS), a typical disorder
that shows renal microangiopathy [32, 33]. Formation of AECA
may explain the occasional association of HUS with some condi-
tions such as pregnancy or oral contraceptive use that accompany
immune dysregulation [31, 34].
These previous studies suggest that generation of AECA and
activation of the complement cascade could play an important
role in the pathogenesis of human renal microangiopathy of
various etiologies. Our results demonstrate that the C5b-9 mem-
brane attack complex plays a major role in the pathogenesis of this
renal TMA model in rats. Identification of a similar pathogenic
role in human TMA may be difficult in view of the demonstration
in this model that the injurious effect of the complement system
occurs very early in the evolution of the disease process.
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APPENDIX
Abbreviations used in this manuscript are: GEN, glomerular endotheial
cell; CVF, cobra venom factor; GEC, glomerular epitheial cells; BUN,
blood urea nitrogen; RECA-1, rat endothelial cell specific monoclonal
antibody; AECA, anti-endothelial cell antibodies; HUS, hemolytic uremic
syndrome.
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